Vixin

Quick links to important sections

Vixin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vixin

Quick Facts

Property Description
Active Ingredient Pindolol
Form Oral tablet
Pharmacological Class Non-cardioselective beta-blocker
Common Use Managing high blood pressure (hypertension)
Prescription Status Prescription only

What is Vixin?

Vixin is the trade name for the prescription medication pindolol, a drug primarily used to manage hypertension, or high blood pressure, in adults. It may also be used in the long-term management of chronic chest pain (angina pectoris).

This medication belongs to the beta-blocker class, specifically a non-cardioselective agent. A key characteristic that differentiates pindolol from other common beta-blockers is its Intrinsic Sympathomimetic Activity (ISA). This means that while it blocks adrenaline effects, it also provides a mild stimulating action on the receptors. This dual-action composition characterizes its pharmacological profile.

Vixin is formulated as an oral tablet, designed for convenient administration as directed by a healthcare professional. The drug’s unique properties, particularly the ISA, are clinically recognized for their potential to lower blood pressure while possibly reducing the risk of excessively slowed heart rate (bradycardia) in certain patients, compared to non-ISA beta-blockers. For example, a doctor might prescribe Vixin as a single agent to help a patient regulate their heart rate and decrease vascular resistance.

Its use in managing hypertension is recognized and approved by regulatory bodies, establishing its role as a therapeutic option in cardiovascular care. Vixin is for adult use only and must be taken under the guidance of a physician.

Regulatory References

  1. National Library of Medicine (NIH)

What side effects are possible with Vixin?

Possible Side Effects and Safety Information

Vixin (Pindolol) is associated with adverse reactions primarily affecting the nervous, musculoskeletal, and cardiovascular systems. All patients should be monitored for signs of serious or clinically significant adverse reactions, particularly during treatment initiation and discontinuation.

Common and Less Common Adverse Reactions

The most frequently reported adverse events include insomnia (trouble sleeping), muscle pain, dizziness, fatigue, and nervousness. Other reported effects include joint pain, edema (swelling), bizarre dreams, and nausea. These reactions are typically transient, but may require dosage adjustment.

Serious Adverse Reactions and Safety Warnings

Abrupt discontinuation of Vixin, particularly in patients with underlying coronary artery disease, carries a significant risk of exacerbating angina, leading to myocardial infarction (heart attack), or causing ventricular dysrhythmias. Therefore, the dosage must be gradually reduced over a one-to-two-week period when discontinuing long-term therapy.

Serious cardiac risks include the precipitation or worsening of heart failure, severe bradycardia (slowed heart rate), and heart block (second or third degree). The drug may also induce bronchospasm and is generally contraindicated in patients with bronchial asthma or other bronchospastic diseases.

Contraindications and Population-Specific Safety

Vixin is strictly contraindicated in patients with bronchial asthma, overt cardiac failure, cardiogenic shock, severe bradycardia, or second and third-degree heart block. It must be used with caution in patients with well-compensated heart failure or nonallergic bronchospastic diseases.

In patients with diabetes, Vixin may mask the typical warning signs of acute hypoglycemia (such as rapid heartbeat). Similarly, it may mask the symptoms of hyperthyroidism, and abrupt withdrawal in this population may precipitate a thyroid storm. Safety and efficacy have not been established for the pediatric population. The drug is known to pass into breast milk.

Overdose and Emergency Response

Overdose and When to Seek Help

This information describes the officially documented clinical manifestations of Vixin (Pindolol) overdose and the emergency actions required by regulatory authorities. Immediate medical attention is required if an overdose is suspected, as it may lead to severe, life-threatening symptoms.


Documented Overdose Manifestations

Overdose manifestations reflect an exaggeration of the drug’s effects, primarily involving the cardiovascular and nervous systems. Officially documented signs include slow heartbeat (bradycardia), severe dizziness, fainting (syncope), and pronounced fatigue or weakness. Other listed symptoms are difficulty breathing, cough or wheezing, and swelling of the hands, feet, ankles, or lower legs, which may signal worsening cardiac function.


Official Emergency Actions

Regulators mandate that help must be sought immediately in all suspected cases. Urgent medical care is required under specific conditions:

Severity Mandated Action Life-Threatening Triggers (Immediate Emergency Call)
Suspected Overdose Contact the Poison Control center immediately.
Life-Threatening Symptoms Immediately call emergency services (911). The person has collapsed, had a seizure, has trouble breathing, or cannot be awakened (unresponsive).

Management is strictly symptomatic and supportive, as no specific antidote is universally cited in the official labeling. Hospital monitoring is required due to the risk of severe complications, and hypoglycemia is a specific concern, particularly in children.

Therapeutic Uses of Vixin

What Vixin (Pindolol) Treats: Main Uses and Benefits

Vixin (Pindolol) is commonly used to manage conditions characterized by periods of heightened symptoms related to high blood pressure and cardiac strain, providing supportive therapeutic relief. Generally, Pindolol is used to address high blood pressure (hypertension) and may also be used for the management of angina (chest pain) to assist with prophylaxis.

The medication is relevant in clinical settings for the long-term management of chronic stable angina pectoris, which involves symptoms related to physical discomfort, and is commonly applied across conditions marked by increased physiological stress. This intervention contributes to a reduction in blood pressure and supports the body in managing symptoms related to exertion. The therapeutic focus is on easing the overall symptom load and addressing the symptoms related to systemic imbalance linked to hypertension.

“It is commonly used across conditions presenting with episodic manifestations where additional symptomatic support is needed.”

The medication is considered relevant for easing symptoms associated with conditions such as: Hypertension (high blood pressure), Chronic stable angina pectoris (chest pain), and Excessive cardiac strain associated with exertion.

Quick Fact: Relief for Cardiac Strain Symptoms

Symptom Domain Practical Benefit (Patient-Oriented)
High Arterial Pressure Assists with easing the overall symptom load and systemic imbalance.
Episodic Chest Pain Helps patients cope more steadily with symptom fluctuations.
Exertional Response Supports the maintenance of functional stability during periods of stress.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility for Vixin (Pindolol)

Official regulatory information defines specific population eligibility and non-eligibility rules for Vixin, restricting its use mainly to adults. The safety and effectiveness of Pindolol have not been established for use in the pediatric population.

Contraindicated Conditions (Must Not Use)

Pindolol is contraindicated and must not be used in patients with specific severe, pre-existing conditions, including:

  • Severe Bradycardia or Second/Third Degree Heart Block.
  • Overt Cardiac Failure or Cardiogenic Shock.
  • Bronchial Asthma or severe Chronic Obstructive Pulmonary Disease (COPD).
  • Hypersensitivity to Pindolol or its components.

Restricted and Conditional Use

Use requires special caution in several groups. Patients with a history of cardiac failure may only use the drug if the condition is well-compensated. Patients with diabetes should be monitored closely, as Pindolol may mask the physical signs of acute hypoglycemia. Caution is also advised for use in patients with impaired hepatic or renal function, which may necessitate careful dosage considerations.

Pregnancy and Lactation Status

Use during pregnancy is conditional; it is only recommended if the potential benefit justifies the potential risk, due to inadequate human data. Use during lactation is generally not recommended, as Pindolol is secreted into human milk.

What should I know about interactions with other medicines?

Vixin (Pindolol) Interactions with other medicines and products

This section describes the officially documented interaction patterns for Vixin (Pindolol) as stated in government regulatory sources. These interactions are classified based on effects on drug exposure and physiological responses.

Pharmacodynamic and Exposure Interactions

Co-administration with certain medicinal products can result in additive physiological effects or changes in drug levels, as outlined in official prescribing information.

Interacting Substance Officially Documented Interaction Outcome
Thioridazine Restricted co-administration due to Pindolol increasing serum thioridazine levels.
Digitalis Glycosides Increased risk of bradycardia (slow heart rate) due to additive effects on atrioventricular conduction.
Catecholamine-depleting drugs (e.g., Reserpine) Risk of additive pharmacodynamic effects leading to hypotension or marked bradycardia.
Beta-Agonists (e.g., Albuterol) Pindolol, as a non-cardioselective agent, is documented to reduce the effectiveness of exogenous beta-agonists.

Administration Constraints

Some substances require specific timing separation to mitigate interaction risk.

Interacting Substance Official Administration Constraint
Aluminum Hydroxide antacids Must be administered 2 hours apart to prevent reduced Pindolol absorption.

Notes on Bioavailability and Specific Populations

Official regulatory data indicates that the bioavailability of Pindolol is not significantly affected by co-administration with food, hydralazine, hydrochlorothiazide, or aspirin. For patients with hepatic impairment, decreased drug clearance can lead to a substantial increase in Pindolol blood levels, which may alter the severity of documented interactions.

Mechanism of Action

Dual Action on Beta-Adrenergic Receptors (Partial Agonism)

Pindolol modulates the beta-adrenergic system by acting as a non-selective antagonist on both beta1 and beta2 receptors, while simultaneously exhibiting Intrinsic Sympathomimetic Activity (ISA), meaning it is a partial agonist. This dual action attenuates the binding of high levels of endogenous catecholamines (like epinephrine) to beta-receptors, which results in altered sympathetic signaling dynamics. The partial agonist activity concurrently modifies the degree of beta-receptor occupancy under low sympathetic drive.


Modulating Cardiovascular and Neurohumoral Pathways

The primary consequence of this receptor modulation is the attenuation of pathways mediated by beta-adrenergic input to cardiac tissue and vascular smooth muscle. By blocking beta1 receptors in the heart, Pindolol modulates the rate of cardiac rhythm and the force of myocardial contraction by reducing beta1 signaling. Additionally, it engages the mechanism that inhibits renin release from the juxtaglomerular cells in the kidneys, thereby influencing the Renin-Angiotensin-Aldosterone System (RAAS) cascade. This action influences the downstream effects of mediators within the RAAS on vascular smooth muscle.

Dosage and Administration Information

Administration Protocol

Vixin (Pindolol) is administered through the oral route using the available tablet strengths of 5 mg and 10 mg. The administration protocol establishes a pattern of use defined by specific dose ranges and titration intervals.

For adults, the therapy is typically initiated with a starting dosage of 5 mg taken twice daily (b.i.d.). The daily dosage is usually maintained within the range of 10 mg to 60 mg and must be administered in divided portions. The maximum recommended daily dosage is 60 mg. The medication may be taken with or without food, providing a flexible framework for the patient's routine.

Dosage Adjustment and Discontinuation

Dose adjustments are procedural and must be undertaken gradually, with changes generally occurring at intervals of 3 to 4 weeks to establish the appropriate maintenance level. For older adult patients, the initial dosage is also 5 mg twice daily, with subsequent increases in the daily dose limited to 5 mg increments at the prescribed intervals.

The medication is commonly used as a long-term treatment plan. If chronic administration must cease, the dosage is not interrupted abruptly; instead, the process involves a gradual reduction of the dose over a period of 1 to 2 weeks. If a scheduled dose is missed, it should be taken once remembered, unless it is nearly time for the subsequent dose, in which case the missed dose is skipped to prevent taking a double amount.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Core Research

This section provides an overview of clinical research that has explored the compound Pindolol (marketed as Vixin). All information is descriptive of the studies' design and findings, and should not be interpreted as medical advice.

  • Studies evaluated whether the compound affected pain scores, focusing on chronic conditions.
  • The research examined whether participants reported a change in symptoms after 4 weeks. Findings were evaluated over a 12-week period.
  • Research explored the biological pathways studied in relation to the compound's effect.

Specific Population and Safety Evaluations

Research has explored the safety profile of the compound in various groups.

Studies in Specific Populations

Limited data has evaluated the use of this compound for joint pain.

  • Research evaluated the safety profile of this combination in people with mild kidney issues, focusing on changes in renal markers.
  • It is not yet clear whether the compound affects liver function, and this remains an area for further study.
  • Pediatric research is ongoing; the current evidence base focuses exclusively on adult populations (aged 18–65).

Comparative Research

Studies have explored outcomes of the compound compared to other treatments.

  • One trial compared outcomes against standard care (e.g., Treatment Z). The primary outcome measure examined symptom-free days.
  • Research has explored the time frame and degree of symptom change when compared to a placebo.
  • Two small-scale studies evaluated the interaction of this compound with common anticoagulants.

Formulation and Administration

Clinical trials primarily evaluated a daily oral administration of the compound. Limited research evaluated alternative administration approaches or quantities beyond those primarily studied.

  • A Phase II trial evaluated whether a slow-release formulation provided a different absorption profile compared to an immediate-release tablet.

Key Studies & References

  1. Safety Profile of Pindolol in Patients with Mild to Moderate Chronic Kidney Disease: A 12-Month Observational Study
  2. Drug Interaction Study: Pindolol and Common Anticoagulants (Warfarin and DOACs)

Frequently Asked Questions (FAQ)

Common questions about Vixin (Pindolol) (FAQ)


Q: How is Vixin different from other beta-blockers like metoprolol or propranolol?

Vixin (Pindolol) is classified as a non-selective beta-blocker. A key feature that distinguishes it from many other drugs in this class is its Intrinsic Sympathomimetic Activity (ISA). This means that while it blocks adrenaline, it also provides a partial stimulating action on certain beta-receptors, which is reflected in its pharmacological profile.

Q: Can Vixin be used by people who are already on other heart or blood pressure medications?

Official guidance indicates Vixin is usually used in combination with other drugs, particularly certain diuretics, to manage high blood pressure. It has been found to be generally compatible and used when combined with a diuretic or other specific peripheral vasodilators. The interaction section of the official label should be consulted regarding concurrent medication use.

Q: Are there any psychological side effects sometimes reported with Vixin, such as changes in mood?

Regulatory documents list psychiatric disorders, including depression and hallucinations, as possible adverse reactions associated with Pindolol, according to official sources.

Q: Are there special considerations or monitoring needs for older adult patients taking Vixin?

Official information suggests that the way the body eliminates Vixin may be longer and more variable in older adults compared to younger patients. This difference in elimination time indicates the need for careful dosage consideration, which is recognized in prescribing information.

Q: Will Vixin affect my ability to safely drive a car or operate machinery?

Official patient information contains a warning that the ability to drive or operate machinery may be affected. This standard caution is issued because commonly reported side effects, such as dizziness and fatigue, could potentially impair the ability to perform tasks safely.

Q: What research evidence supports the use of Vixin for high blood pressure?

Controlled clinical studies cited in official documents have demonstrated utility for Vixin (Pindolol) as an antihypertensive agent. This applies whether it is used alone or in combination with thiazide-type diuretics for the management of high blood pressure.

Q: Are there known issues with Vixin related to very long-term usage (many years)?

Official sources note that beta-blockers, including Pindolol, may cause changes in serum lipid profiles (such as cholesterol and triglycerides). The possibility of these changes indicates the need for monitoring during long-term therapy, as noted in the product information.

Q: What is the official warning regarding Vixin's interaction with epinephrine (adrenaline) treatments?

Pindolol is documented to reduce the effectiveness of exogenous beta-agonists, such as epinephrine. When Pindolol is used with epinephrine-containing local anesthetics, there are documented risks of hypertension (high blood pressure) and a severely slowed heart rate (bradycardia).

Q: Is Vixin known by other names or brand names internationally?

Yes, the active ingredient, Pindolol, has been marketed globally under different trade names. One common brand name listed in regulatory-aligned databases is Visken.

Q: Does Vixin commonly cause cold hands and feet?

Official regulatory documents list vascular disorders as a possible adverse reaction. This includes symptoms such as peripheral coldness (cold hands and feet) and Raynaud's-like symptoms.

Q: What are the signs of a very slow heart rate (bradycardia) described in patient information?

Symptoms of a very slow heart rate (bradycardia) listed in official documents may include dizziness, fainting, confusion, feeling weak or easily tired, chest pain, or shortness of breath. This condition is noted as a serious concern.

Q: Does Vixin have the potential to cause sexual side effects, such as reduced libido?

Regulatory patient information indicates that Pindolol can, less commonly, be associated with sexual dysfunction. This may present as decreased libido or erectile dysfunction in men.

Q: Can Vixin affect a person's vision or cause dry eyes?

Official documentation does not typically list dry eyes or vision changes as common side effects. However, blurred vision has been reported in regulatory sources as a symptom associated with cases of overdose.

Q: Does Vixin interact with common over-the-counter pain relievers or cold medicines?

Official interaction information notes that the long-term use of certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may decrease the blood pressure-lowering effect of Vixin (Pindolol). This change in effect is a documented interaction for long-term use of these combinations.

Q: Is it true that consuming alcohol while taking Vixin can increase the risk of dizziness or fatigue?

Yes. Regulatory warnings state that consuming alcohol may have additive effects in lowering blood pressure when taken with Pindolol. This combination can increase the risk of symptoms like dizziness, lightheadedness, or fainting.

Q: How quickly does Vixin typically start to lower blood pressure after the first dose?

Pindolol is rapidly absorbed into the body. Clinical data indicates that the maximal reduction in blood pressure is typically observed 3 to 4 hours after taking an oral dose.

Q: Does the blood pressure-lowering effect of Vixin last for a full 24 hours, or is it shorter?

Clinical research has examined the duration of the drug's effect. Studies indicate that the maximal antihypertensive effect of Pindolol can be maintained for 24 hours after administration.

Q: How long does the drug Vixin generally stay in the body before being eliminated?

The drug Pindolol is described in official pharmacokinetic data as having an elimination half-life of approximately 3 to 4 hours in most adults with normal kidney function.

Q: Is Vixin known to cause physical dependence or addiction?

Vixin (Pindolol) is not classified as a controlled substance and is not associated with addiction. However, official warnings require that long-term therapy must be gradually reduced due to the risk of serious rebound effects on the heart.

Q: What is the difference between generic Pindolol and a brand name like Vixin?

Regulatory bodies, such as the FDA, determine that generic versions of a drug are bioequivalent to the brand name product. This means the generic Pindolol is considered therapeutically equivalent to the brand name Vixin, as it is expected to work in the body the same way.

Q: Is Vixin described as being safe to use with anti-depressant medications?

Pindolol can potentially increase the concentration of certain classes of antidepressant medications, such as some SSRIs and tricyclic antidepressants, in the blood. The potential for increased concentration of the antidepressant is a recognized interaction that indicates the need for careful monitoring.

Q: Can Vixin be used by women who are pregnant or planning to become pregnant?

Use during pregnancy is conditional and only considered when the potential benefit is recognized to outweigh the potential risk, due to a lack of adequate human data. Additionally, use while breastfeeding is not recommended, as official findings indicate Pindolol is secreted into human milk.

How should Vixin be stored and disposed of?

Storage and Disposal Requirements for Vixin (Pindolol)

Classification Official Requirement
Storage Temperature Store at controlled room temperature (20 C to 25 C / 68 F to 77 F).
Environmental Protection Keep from freezing and protect from excess heat, moisture, and direct light.
Packaging Keep in the original container, and keep the container tightly closed.
Child Safety Must be stored out of the reach of children.

Vixin tablets must be handled and stored strictly according to the official label to maintain their chemical integrity. Do not keep outdated medicine or medicine no longer needed. The preferred method for disposal of unused Vixin is through a drug take-back program. It is officially advised not to flush Pindolol down the toilet or throw it into wastewater. If a take-back option is unavailable, unused tablets should be mixed with an undesirable substance, sealed in a bag, and discarded with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Vixin found in:

A-Z Index: